These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 30547573)

  • 21. A selective allosteric potentiator of the M1 muscarinic acetylcholine receptor increases activity of medial prefrontal cortical neurons and restores impairments in reversal learning.
    Shirey JK; Brady AE; Jones PJ; Davis AA; Bridges TM; Kennedy JP; Jadhav SB; Menon UN; Xiang Z; Watson ML; Christian EP; Doherty JJ; Quirk MC; Snyder DH; Lah JJ; Levey AI; Nicolle MM; Lindsley CW; Conn PJ
    J Neurosci; 2009 Nov; 29(45):14271-86. PubMed ID: 19906975
    [TBL] [Abstract][Full Text] [Related]  

  • 22. M1 muscarinic allosteric modulators slow prion neurodegeneration and restore memory loss.
    Bradley SJ; Bourgognon JM; Sanger HE; Verity N; Mogg AJ; White DJ; Butcher AJ; Moreno JA; Molloy C; Macedo-Hatch T; Edwards JM; Wess J; Pawlak R; Read DJ; Sexton PM; Broad LM; Steinert JR; Mallucci GR; Christopoulos A; Felder CC; Tobin AB
    J Clin Invest; 2017 Feb; 127(2):487-499. PubMed ID: 27991860
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Synthesis and pharmacological evaluation of analogues of benzyl quinolone carboxylic acid (BQCA) designed to bind irreversibly to an allosteric site of the M ₁ muscarinic acetylcholine receptor.
    Davie BJ; Valant C; White JM; Sexton PM; Capuano B; Christopoulos A; Scammells PJ
    J Med Chem; 2014 Jun; 57(12):5405-18. PubMed ID: 24856614
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Further exploration of M₁ allosteric agonists: subtle structural changes abolish M₁ allosteric agonism and result in pan-mAChR orthosteric antagonism.
    Sheffler DJ; Sevel C; Le U; Lovell KM; Tarr JC; Carrington SJ; Cho HP; Digby GJ; Niswender CM; Conn PJ; Hopkins CR; Wood MR; Lindsley CW
    Bioorg Med Chem Lett; 2013 Jan; 23(1):223-7. PubMed ID: 23200253
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Allosteric modulators of M
    Widman CJ; Ventresca S; Dietrich J; Elmslie G; Smith H; Kaup G; Wesley A; Doenecke M; Williams FE; Schiefer IT; Ellis J; Messer WS
    Sci Rep; 2024 Jun; 14(1):14901. PubMed ID: 38942828
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Discovery of a novel class of heteroaryl-pyrrolidinones as positive allosteric modulators of the muscarinic acetylcholine receptor M
    Spearing PK; Cho HP; Luscombe VB; Blobaum AL; Boutaud O; Engers DW; Rodriguez AL; Niswender CM; Jeffrey Conn P; Lindsley CW; Bender AM
    Bioorg Med Chem Lett; 2021 Sep; 47():128193. PubMed ID: 34118412
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Therapeutic potential of TAK-071, a muscarinic M
    Kurimoto E; Yamada R; Hirakawa T; Kimura H
    Neurosci Lett; 2021 Nov; 764():136240. PubMed ID: 34509568
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Molecular Mechanisms of Action of M5 Muscarinic Acetylcholine Receptor Allosteric Modulators.
    Berizzi AE; Gentry PR; Rueda P; Den Hoedt S; Sexton PM; Langmead CJ; Christopoulos A
    Mol Pharmacol; 2016 Oct; 90(4):427-36. PubMed ID: 27461343
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Differential regulation of muscarinic M1 receptors by orthosteric and allosteric ligands.
    Davis CN; Bradley SR; Schiffer HH; Friberg M; Koch K; Tolf BR; Bonhaus DW; Lameh J
    BMC Pharmacol; 2009 Dec; 9():14. PubMed ID: 19951444
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmacological characterization of LY593093, an M1 muscarinic acetylcholine receptor-selective partial orthosteric agonist.
    Watt ML; Schober DA; Hitchcock S; Liu B; Chesterfield AK; McKinzie D; Felder CC
    J Pharmacol Exp Ther; 2011 Aug; 338(2):622-32. PubMed ID: 21558436
    [TBL] [Abstract][Full Text] [Related]  

  • 31. M
    Hassani SA; Neumann A; Russell J; Jones CK; Womelsdorf T
    Proc Natl Acad Sci U S A; 2023 May; 120(18):e2216792120. PubMed ID: 37104474
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Orthosteric and allosteric modes of interaction of novel selective agonists of the M1 muscarinic acetylcholine receptor.
    Avlani VA; Langmead CJ; Guida E; Wood MD; Tehan BG; Herdon HJ; Watson JM; Sexton PM; Christopoulos A
    Mol Pharmacol; 2010 Jul; 78(1):94-104. PubMed ID: 20413650
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Structure-Activity Relationships of Pan-Gα
    Berizzi AE; Bender AM; Lindsley CW; Conn PJ; Sexton PM; Langmead CJ; Christopoulos A
    ACS Chem Neurosci; 2018 Jul; 9(7):1818-1828. PubMed ID: 29683647
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Reverse engineering of the selective agonist TBPB unveils both orthosteric and allosteric modes of action at the M₁ muscarinic acetylcholine receptor.
    Keov P; Valant C; Devine SM; Lane JR; Scammells PJ; Sexton PM; Christopoulos A
    Mol Pharmacol; 2013 Sep; 84(3):425-37. PubMed ID: 23798605
    [TBL] [Abstract][Full Text] [Related]  

  • 35. PF-06827443 Displays Robust Allosteric Agonist and Positive Allosteric Modulator Activity in High Receptor Reserve and Native Systems.
    Moran SP; Cho HP; Maksymetz J; Remke DH; Hanson RM; Niswender CM; Lindsley CW; Rook JM; Conn PJ
    ACS Chem Neurosci; 2018 Sep; 9(9):2218-2224. PubMed ID: 29683646
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Evidence for Classical Cholinergic Toxicity Associated with Selective Activation of M1 Muscarinic Receptors.
    Alt A; Pendri A; Bertekap RL; Li G; Benitex Y; Nophsker M; Rockwell KL; Burford NT; Sum CS; Chen J; Herbst JJ; Ferrante M; Hendricson A; Cvijic ME; Westphal RS; O'Connell J; Banks M; Zhang L; Gentles RG; Jenkins S; Loy J; Macor JE
    J Pharmacol Exp Ther; 2016 Feb; 356(2):293-304. PubMed ID: 26582730
    [TBL] [Abstract][Full Text] [Related]  

  • 37. M1 muscarinic acetylcholine receptors: A therapeutic strategy for symptomatic and disease-modifying effects in Alzheimer's disease?
    Scarpa M; Hesse S; Bradley SJ
    Adv Pharmacol; 2020; 88():277-310. PubMed ID: 32416870
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Dronedarone Modulates M1 and M3 Muscarinic Receptors with Subtype Selectivity, Functional Selectivity, and Probe Dependence.
    Jayasuriya GM; Elmslie G; Burstein ES; Ellis J
    Pharmacology; 2017; 99(3-4):128-138. PubMed ID: 27992867
    [TBL] [Abstract][Full Text] [Related]  

  • 39. T-495, a novel low cooperative M
    Mandai T; Sako Y; Kurimoto E; Shimizu Y; Nakamura M; Fushimi M; Maeda R; Miyamoto M; Kimura H
    Pharmacol Res Perspect; 2020 Feb; 8(1):e00560. PubMed ID: 31990455
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Molecular mechanisms of action and in vivo validation of an M4 muscarinic acetylcholine receptor allosteric modulator with potential antipsychotic properties.
    Leach K; Loiacono RE; Felder CC; McKinzie DL; Mogg A; Shaw DB; Sexton PM; Christopoulos A
    Neuropsychopharmacology; 2010 Mar; 35(4):855-69. PubMed ID: 19940843
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.